Switching adult patients with spasticity from onabotulinumtoxinA to abobotulinumtoxinA: a real-world data analysis across three US-based treatment centers.

Nate Way¹, Edward Dabrowski², Mitchell Paulin³, Martin Taylor⁴, John Madden⁵, Amandeep Mann⁵, Jonathan Bouchard⁵

¹Real World Evidence, Cerner Enviza, an Oracle Company, Malvern, PA 19301, USA.

²Beaumont Health, Royal Oak, MI 48073, USA.

³The Center for Tone Management of the Main Line, Paoli, PA 19301, USA.

⁴OrthoNeuro, New Albany, OH 43054, USA.

⁵Ipsen, Cambridge, MA 02142, USA.

PubMed PMC DOI PDF

Abstract

Aim: To assess patient characteristics, treatment patterns, botulinum toxin type-A (BoNT-A) costs and describe safety in adults with spasticity who switched from onabotulinumtoxinA to abobotulinumtoxinA. Materials & methods: Chart data from three US-based treatment centers was collected in patients aged ≥18 years with upper limb (ULS), lower limb (LLS) or ULS and LLS (ULS + LLS) spasticity. Eligib…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.